# Lenvatinib Combined With TACE to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma

> **NCT03838796** · NA · UNKNOWN · sponsor: **Fudan University** · enrollment: 297 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** lenvatinib
- **PROCEDURE:** TACE

## Key facts

- **NCT ID:** NCT03838796
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-01-03
- **Primary completion:** 2022-06-30
- **Final completion:** 2023-06
- **Target enrollment:** 297 (ACTUAL)
- **Last updated:** 2022-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03838796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03838796, "Lenvatinib Combined With TACE to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03838796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*